FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017108710> ?p ?o ?g. }

• W2017108710 endingPage "811" @default.
• W2017108710 startingPage "806" @default.
• W2017108710 abstract "The effect of in vivo and in vitro N-acetylcysteine (NAC) treatment on destructive activity of macrophages against Candida from COPD patients has been evaluated. Patients received NAC (600 mg) or placebo orally 3 times a day for 15 days and bronchoalveolar lavage (BAL) fluid and peripheral blood were collected before and at the conclusion of treatment. In our system, NAC treatment was not able to modulate antifungal activity of alveolar macrophages, peripheral blood monocytes (PBM), and polymorphonuclear leukocytes. On the contrary, in vitro NAC treatment at appropriate doses (10 µg/ml) significantly enhanced antifungal activity of PBM from COPD patients. This phenomenon is mediated by augmented phagocytic activity and phagosome-lysosome fusion. The lack of correlation between in vivo and in vitro studies could be ascribed to differences in the intracellular concentration of the drug that in vivo does not reach levels capable of inducing macrophage activation. We speculate that in COPD patients who undergo long-term NAC treatment, appropriate schedules and doses of the drug could augment resistance against microbial infections which are often life-threatening in these patients. The effect of in vivo and in vitro N-acetylcysteine (NAC) treatment on destructive activity of macrophages against Candida from COPD patients has been evaluated. Patients received NAC (600 mg) or placebo orally 3 times a day for 15 days and bronchoalveolar lavage (BAL) fluid and peripheral blood were collected before and at the conclusion of treatment. In our system, NAC treatment was not able to modulate antifungal activity of alveolar macrophages, peripheral blood monocytes (PBM), and polymorphonuclear leukocytes. On the contrary, in vitro NAC treatment at appropriate doses (10 µg/ml) significantly enhanced antifungal activity of PBM from COPD patients. This phenomenon is mediated by augmented phagocytic activity and phagosome-lysosome fusion. The lack of correlation between in vivo and in vitro studies could be ascribed to differences in the intracellular concentration of the drug that in vivo does not reach levels capable of inducing macrophage activation. We speculate that in COPD patients who undergo long-term NAC treatment, appropriate schedules and doses of the drug could augment resistance against microbial infections which are often life-threatening in these patients." @default.
• W2017108710 created "2016-06-24" @default.
• W2017108710 creator A5014579643 @default.
• W2017108710 creator A5034688668 @default.
• W2017108710 creator A5051777748 @default.
• W2017108710 creator A5053885290 @default.
• W2017108710 creator A5073167511 @default.
• W2017108710 creator A5077940515 @default.
• W2017108710 creator A5080787063 @default.
• W2017108710 date "1994-03-01" @default.
• W2017108710 modified "2023-10-18" @default.
• W2017108710 title "Macrophage Activation by N-Acetyl-cysteine in COPD Patients" @default.
• W2017108710 cites W1557224474 @default.
• W2017108710 cites W1775749144 @default.
• W2017108710 cites W1808379566 @default.
• W2017108710 cites W1855713823 @default.
• W2017108710 cites W1909601209 @default.
• W2017108710 cites W1943399209 @default.
• W2017108710 cites W2004405778 @default.
• W2017108710 cites W2008672993 @default.
• W2017108710 cites W2024675506 @default.
• W2017108710 cites W2034335865 @default.
• W2017108710 cites W2037696254 @default.
• W2017108710 cites W2041310348 @default.
• W2017108710 cites W2047117412 @default.
• W2017108710 cites W2051602839 @default.
• W2017108710 cites W2071095297 @default.
• W2017108710 cites W2088509118 @default.
• W2017108710 cites W2089242226 @default.
• W2017108710 cites W2098128724 @default.
• W2017108710 cites W2100771117 @default.
• W2017108710 cites W2131877061 @default.
• W2017108710 cites W2145998595 @default.
• W2017108710 cites W2156706094 @default.
• W2017108710 cites W2159168765 @default.
• W2017108710 cites W2207489706 @default.
• W2017108710 cites W2336541137 @default.
• W2017108710 cites W40248730 @default.
• W2017108710 cites W4214481755 @default.
• W2017108710 cites W4236681243 @default.
• W2017108710 doi "https://doi.org/10.1378/chest.105.3.806" @default.
• W2017108710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8131544" @default.
• W2017108710 hasPublicationYear "1994" @default.
• W2017108710 type Work @default.
• W2017108710 sameAs 2017108710 @default.
• W2017108710 citedByCount "24" @default.
• W2017108710 countsByYear W20171087102012 @default.
• W2017108710 countsByYear W20171087102013 @default.
• W2017108710 countsByYear W20171087102015 @default.
• W2017108710 countsByYear W20171087102016 @default.
• W2017108710 countsByYear W20171087102018 @default.
• W2017108710 countsByYear W20171087102022 @default.
• W2017108710 crossrefType "journal-article" @default.
• W2017108710 hasAuthorship W2017108710A5014579643 @default.
• W2017108710 hasAuthorship W2017108710A5034688668 @default.
• W2017108710 hasAuthorship W2017108710A5051777748 @default.
• W2017108710 hasAuthorship W2017108710A5053885290 @default.
• W2017108710 hasAuthorship W2017108710A5073167511 @default.
• W2017108710 hasAuthorship W2017108710A5077940515 @default.
• W2017108710 hasAuthorship W2017108710A5080787063 @default.
• W2017108710 hasConcept C126322002 @default.
• W2017108710 hasConcept C150903083 @default.
• W2017108710 hasConcept C202751555 @default.
• W2017108710 hasConcept C203014093 @default.
• W2017108710 hasConcept C207001950 @default.
• W2017108710 hasConcept C2776780178 @default.
• W2017108710 hasConcept C2777714996 @default.
• W2017108710 hasConcept C2777847592 @default.
• W2017108710 hasConcept C2777961210 @default.
• W2017108710 hasConcept C2778004101 @default.
• W2017108710 hasConcept C2778012055 @default.
• W2017108710 hasConcept C2779244956 @default.
• W2017108710 hasConcept C2781264782 @default.
• W2017108710 hasConcept C55493867 @default.
• W2017108710 hasConcept C71924100 @default.
• W2017108710 hasConcept C86803240 @default.
• W2017108710 hasConcept C8891405 @default.
• W2017108710 hasConcept C98274493 @default.
• W2017108710 hasConceptScore W2017108710C126322002 @default.
• W2017108710 hasConceptScore W2017108710C150903083 @default.
• W2017108710 hasConceptScore W2017108710C202751555 @default.
• W2017108710 hasConceptScore W2017108710C203014093 @default.
• W2017108710 hasConceptScore W2017108710C207001950 @default.
• W2017108710 hasConceptScore W2017108710C2776780178 @default.
• W2017108710 hasConceptScore W2017108710C2777714996 @default.
• W2017108710 hasConceptScore W2017108710C2777847592 @default.
• W2017108710 hasConceptScore W2017108710C2777961210 @default.
• W2017108710 hasConceptScore W2017108710C2778004101 @default.
• W2017108710 hasConceptScore W2017108710C2778012055 @default.
• W2017108710 hasConceptScore W2017108710C2779244956 @default.
• W2017108710 hasConceptScore W2017108710C2781264782 @default.
• W2017108710 hasConceptScore W2017108710C55493867 @default.
• W2017108710 hasConceptScore W2017108710C71924100 @default.
• W2017108710 hasConceptScore W2017108710C86803240 @default.
• W2017108710 hasConceptScore W2017108710C8891405 @default.
• W2017108710 hasConceptScore W2017108710C98274493 @default.
• W2017108710 hasIssue "3" @default.
• W2017108710 hasLocation W20171087101 @default.

• next